These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 32976740)

  • 1. Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition.
    Kim HJ; Cantor H; Cosmopoulos K
    Trends Immunol; 2020 Oct; 41(10):948-963. PubMed ID: 32976740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy.
    Sun S; Yu F; Xu D; Zheng H; Li M
    Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188700. PubMed ID: 35217116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer.
    Shin DS; Park K; Garon E; Dubinett S
    Semin Oncol; 2022 Jun; 49(3-4):306-318. PubMed ID: 35851153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations.
    Qiu J; Sharma S; Rollins RA; Paul TA
    Future Med Chem; 2020 Aug; 12(15):1415-1430. PubMed ID: 32723083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
    Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
    Front Immunol; 2020; 11():784. PubMed ID: 32457745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
    Yang X; Li F; Konze KD; Meslamani J; Ma A; Brown PJ; Zhou MM; Arrowsmith CH; Kaniskan HÜ; Vedadi M; Jin J
    J Med Chem; 2016 Aug; 59(16):7617-33. PubMed ID: 27468126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 inhibition: a promising strategy to prevent cancer immune editing.
    Kang N; Eccleston M; Clermont PL; Latarani M; Male DK; Wang Y; Crea F
    Epigenomics; 2020 Aug; 12(16):1457-1476. PubMed ID: 32938196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
    Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
    Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies.
    Ajina R; Zahavi DJ; Zhang YW; Weiner LM
    Semin Cancer Biol; 2020 Oct; 65():28-37. PubMed ID: 31866479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade.
    Hoffmann F; Niebel D; Aymans P; Ferring-Schmitt S; Dietrich D; Landsberg J
    Clin Epigenetics; 2020 Feb; 12(1):24. PubMed ID: 32041674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
    Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
    Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The functions of EZH2 in immune cells: Principles for novel immunotherapies.
    Shao FF; Chen BJ; Wu GQ
    J Leukoc Biol; 2021 Jul; 110(1):77-87. PubMed ID: 33040370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Therapy Opportunities in Ovarian Cancer.
    Kandalaft LE; Odunsi K; Coukos G
    Am Soc Clin Oncol Educ Book; 2020 May; 40():1-13. PubMed ID: 32412818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
    Christofides A; Karantanos T; Bardhan K; Boussiotis VA
    Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism.
    Hamaidia M; Gazon H; Hoyos C; Hoffmann GB; Louis R; Duysinx B; Willems L
    JCI Insight; 2019 Sep; 4(18):. PubMed ID: 31534051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance.
    Bell HN; Zou W
    Annu Rev Immunol; 2024 Jun; 42(1):521-550. PubMed ID: 38382538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 inhibitors: a patent review (2014-2016).
    Stazi G; Zwergel C; Mai A; Valente S
    Expert Opin Ther Pat; 2017 Jul; 27(7):797-813. PubMed ID: 28394193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting EZH2 in cancer therapy.
    Yamagishi M; Uchimaru K
    Curr Opin Oncol; 2017 Sep; 29(5):375-381. PubMed ID: 28665819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2-associated tumor malignancy: A prominent target for cancer treatment.
    Sabour-Takanlou M; Sabour-Takanlou L; Biray-Avci C
    Clin Genet; 2024 Oct; 106(4):377-385. PubMed ID: 38881299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming T Cell Exhaustion in Tumor Microenvironment via Immune Checkpoint Modulation with Nano-Delivery Systems for Enhanced Immunotherapy.
    Huang X; Zhang W
    Small Methods; 2024 Aug; 8(8):e2301326. PubMed ID: 38040834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.